Journal of
AIDS and HIV Research

  • Abbreviation: J. AIDS HIV Res.
  • Language: English
  • ISSN: 2141-2359
  • DOI: 10.5897/JAHR
  • Start Year: 2009
  • Published Articles: 297

Case Report

Safe use of Sunitinib in metastatic non-clear cell renal cell cancer in the setting of human immunodeficiency virus

Govender P. S.
  • Govender P. S.
  • P. O. Box 3019, Sunningdale, Durban, 4019 South Africa.
  • Search for this author on:
  • Google Scholar
Abdel Goad E. H.
  • Abdel Goad E. H.
  • P. O. Box 3019, Sunningdale, Durban, 4019 South Africa.
  • Search for this author on:
  • Google Scholar


  •  Accepted: 19 October 2011
  •  Published: 30 November 2011

Abstract

The introduction of targeted therapies has offered the promise of better survival outcomes for patients with metastatic renal cell carcinoma. Sunitinib malate, an oral, multitargeted tyrosine kinase inhibitor, is an important treatment option for patients with metastatic renal cell carcinoma. This case study explores the controversial use of sunitinib in a patient with a non-clear cell variant of renal cell carcinoma, also on treatment with combined antiretroviral treatment for a co-existing human immunodeficiency virus infection.

 

Key words: Sunitinib, non-clear cell metastatic renal cell carcinoma, human immunodeficiency virus and antiretroviral treatment.

Copyright © 2024 Author(s) retain the copyright of this article.

This article is published under the terms of the Creative Commons Attribution License 4.0

Back to Vol. 3 No. 11
Back to articles
SUBSCRIBE TO RSS
SUBMIT MANUSCRIPT
CONFERENCES